Literature DB >> 25034572

Identification of treatment goals in paediatric pulmonary arterial hypertension.

Mark-Jan Ploegstra1, Johannes M Douwes2, Marcus T R Roofthooft2, Willemijn M H Zijlstra2, Hans L Hillege3, Rolf M F Berger2.   

Abstract

To be able to design goal-oriented treatment strategies in paediatric pulmonary arterial hypertension (PAH), we aimed to identify treatment goals by investigating the prognostic value of treatment-induced changes in noninvasive predictors of transplant-free survival. 66 consecutive, treatment-naïve paediatric PAH patients in the Dutch National Network for Paediatric Pulmonary Hypertension who started taking PAH-targeted drugs between January 2000 and April 2013 underwent prospective, standardised follow-up. Clinical, biochemical and echocardiographic measures were longitudinally collected at treatment initiation and follow-up, and their respective predictive values for transplant-free survival were assessed. Furthermore, the predictive values of treatment-induced changes were assessed. From the identified set of baseline predictors, the variables World Health Organization functional class (WHO-FC), N-terminal pro-brain natriuretic peptide (NT-proBNP) and tricuspid annular plane systolic excursion (TAPSE) were identified as follow-up predictors in which treatment-induced changes were associated with survival. Patients in whom these variables improved after treatment showed better survival (p<0.002). Therefore, WHO-FC, NT-proBNP and TAPSE are not only predictors of transplant-free survival in paediatric PAH but can also be used as treatment goals, as treatment-induced improvements in these variables are associated with improved survival. The identification of these variables allows for the introduction of goal-oriented treatment strategies in paediatric PAH. ©ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034572     DOI: 10.1183/09031936.00030414

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

Review 1.  Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction.

Authors:  Martin Koestenberger; Mark K Friedberg; Eirik Nestaas; Ina Michel-Behnke; Georg Hansmann
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 2.  B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.

Authors:  Chantal A Ten Kate; Dick Tibboel; Ulrike S Kraemer
Journal:  Eur J Pediatr       Date:  2015-08-23       Impact factor: 3.183

3.  Right ventricular-vascular coupling ratio in pediatric pulmonary arterial hypertension: A comparison between cardiac magnetic resonance and right heart catheterization measurements.

Authors:  K T N Breeman; M Dufva; M J Ploegstra; V Kheyfets; T P Willems; J Wigger; K S Hunter; D D Ivy; R M F Berger; U Truong
Journal:  Int J Cardiol       Date:  2019-05-10       Impact factor: 4.164

4.  Prostanoids in pediatric pulmonary hypertension: clinical response, time-to-effect, and dose-response.

Authors:  Joseph B Tella; Thomas J Kulik; Julia E McSweeney; Lynn A Sleeper; Minmin Lu; Mary P Mullen
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

5.  Home Exercise Training in Children and Adolescents with Pulmonary Arterial Hypertension: A Pilot Study.

Authors:  David Zöller; Jannos Siaplaouras; Anita Apitz; Peter Bride; Michael Kaestner; Heiner Latus; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2016-11-14       Impact factor: 1.655

6.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

Review 7.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

Review 8.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 9.  Persistent Challenges in Pediatric Pulmonary Hypertension.

Authors:  Rachel K Hopper; Steven H Abman; D Dunbar Ivy
Journal:  Chest       Date:  2016-01-22       Impact factor: 9.410

10.  Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study.

Authors:  Maurice Beghetti; Rolf M F Berger; Damien Bonnet; Simon Grill; Catherine Lesage; Jean-Christophe Lemarie; D Dunbar Ivy
Journal:  Front Pediatr       Date:  2021-06-16       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.